Functional characterization of T3SS C-ring component VscQ and evaluation of its mutant as a live attenuated vaccine in zebrafish (Danio rerio) model
Publication date: Available online 27 May 2020Source: Fish &Shellfish ImmunologyAuthor(s): Peiwen Wu, Shihui Zhou, Zehui Su, Chang Liu, Fuyuan Zeng, Huanying Pang, Miao Xie, Jichang Jian
Publication date: Available online 13 July 2020Source: Veterinary MicrobiologyAuthor(s): Eda Baldan Toker, Gizem Aytogu, Berfin Kadiroglu, OzerAtes, Kadir Yesilbag
Immune responses triggered in 45 participants in phase one trial, without safety issues
Saying it plans to launch what will likely be one of the largest clinical trials the drug industry has seen before in less than two weeks, Moderna Inc. revealed more evidence from an early-stage trial of its potential vaccine that indicated it could be successful. Moderna (Nasdaq: MRNA) released the data from the first test of its Covid-19 vaccine after markets closed Tuesday, which included 42 of the 45 subjects originally enrolled in the NIH-led study (An additional 110 subjects were enrolled…
Some experts say a vaccine puffed in the nose would be better at protecting people from infection. But nasal vaccines won ’t be ready right away.
Exactly how Americans will greet a COVID-19 vaccine is unknown, but polls have suggested many will be wary.
NIH-sponsored Phase 1 trial tested mRNA vaccine.
Here is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.Reuters Health Information
Condition: COVID-19 Interventions: Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: Placebo on a 0- a nd 28-day schedule Sponsors: Chinese Academy of Medical Sciences; West China Second University Hospital; Yunnan Center for Disease Control and Preventi...
Condition: SARS-CoV-2 Interventions: Biological: mRNA-1273; Biological: Placebo Sponsors: ModernaTX, Inc.; Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Condition: Cancer of the Head and Neck Interventions: Drug: INCAGN01876; Drug: INCMGA00012; Biological: DPV-001 Sponsor: Providence Health & Services Not yet recruiting